IGF-1 LR3
Long-acting IGF-1 analog discussed in muscle and recovery research (non-approved summary).
Overview
Distinct pharmacokinetics from endocrine IGF-1 — regulatory and safety concerns.
What it is
Synthetic IGF-1 variant with extended half-life (LR3).
Mechanism (high level)
IGF-1 receptor signaling promotes anabolism; hypoglycemia risk is a key concern.
Quick facts
- Dosage
- No approved consumer dosing
- Route
- SubQ/IM in discussion
- Cycle
- Not standardized
- Storage
- Lyophilized cold storage typical
Research indications
- Muscle and metabolism preclinical models
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Insulin and sulfonylureas without supervision
Often combined with
- Frequent meals if hypoglycemia risk
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- Hypoglycemia, organomegaly concerns in animal data — not recreational.
Regulatory notes
- Not approved for OTC performance use.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.